FDA clears AI-powered image reconstruction technology for cardiac CT scanners

“Today, fewer than 5% of U.S. patients that need cardiac CT are getting appropriately scanned due to lack of access at point-of-care,” Arineta CEO Scott Schubert said in a statement. “This FDA clearance continues Arineta’s vision and leadership to make cardiac CT the front-line imaging test for patients with chest pain and suspected cardiovascular disease, as recommended by the ACC and AHA 2021 guidelines.”

“We have used Arineta cardiac CT systems for several years, and they provide the highest quality cardiac CT clinical images for our practice,” Matthew Budoff, MD, a preventive cardiologist with the David Geffen School of Medicine at the University of California Los Angeles, added in the same statement.